Solventum vs Steris
SOLV and STE side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SOLV and STE compare
Steris is the larger company, worth 1.7 times as much as Solventum ($25.0B against $15.1B).
On earnings, Steris is cheaper: it trades at 30.4× trailing earnings, against 99.6× for Solventum.
Steris grew revenue faster over the last twelve months (8.1% versus −2.8% for Solventum).
Steris keeps more of each dollar of sales as profit, with a net margin of 13.4% compared with 1.9% at Solventum.
Steris pays a dividend yielding 0.76%; Solventum does not pay one.
Steris scores higher on the StockData Score (21 against 6 for Solventum), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SOLV | STE |
|---|---|---|
| Size and price | ||
| Market cap | $15.1B | $25.0B |
| Share price | $88.62 | $256.27 |
| Change, 1 year | 23.4% | −2.9% |
| Change, 5 years | – | 9.7% |
| Beta (5Y) | 0.52 | 0.75 |
| Employees | 10K | 17K |
| StockData Score | ||
| Total score | 6 | 21 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 2 | 3 (better) |
| Performance score | 2 | 5 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/E | 99.6× | 30.4× (better) |
| P/S | 1.8× (better) | 4.1× |
| P/B | 3.1× (better) | 3.4× |
| EV/EBITDA | 20.2× | 15.8× (better) |
| P/FCF | – | 26.7× |
| PEG | 22.09 | 0.32 (better) |
| FCF yield | 0.00% | 3.8% (better) |
| Fair value | $46.13 | $263.15 |
| Margin of safety | −92.1% | 2.6% (better) |
| Growth | ||
| Revenue growth (TTM) | −2.8% | 8.1% (better) |
| Revenue growth, 5Y average | – | 13.8% |
| Net income growth (TTM) | −89.8% | 20.1% (better) |
| EPS growth (TTM) | −89.8% | 21.3% (better) |
| EPS growth, 5Y average | – | 11.4% |
| Profitability | ||
| Gross margin | 54.8% (better) | 44.6% |
| Operating margin | 5.6% | 19.0% (better) |
| Net margin | 1.9% | 13.4% (better) |
| FCF margin | 0.00% | 15.2% (better) |
| Return on equity | 3.2% | 11.6% (better) |
| Return on invested capital | 4.7% | 10.0% (better) |
| Financial health | ||
| Debt / equity | 1.05 | 0.26 (better) |
| Net debt / EBITDA | 4.74 | 0.82 (better) |
| Interest coverage | – | 20.5× |
| Current ratio | 1.03 | 2.05 (better) |
| Altman Z-score | 1.85 | 5.87 (better) |
| Piotroski F-score | 5 | 9 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.76% |
| Payout ratio | – | 30.5% |
| Years of dividend growth | – | 9 |
| Dividend growth, 5Y average | – | 9.4% |
| Buyback yield | – | 1.4% |
| Shareholder yield | 0.00% | 2.1% (better) |
| Ownership | ||
| Held by institutions | 75.0% | 97.4% |
| Held by insiders | 30.3% | 0.34% |
| Insider net buying, 12 months | $100K (better) | −$3.2M |
| Superinvestors holding | 2 | – |
| Short interest, % of float | 4.3% | 2.2% |
Go deeper
- SOLV stock overview
- SOLV income statement
- SOLV valuation and score
- STE stock overview
- STE income statement
- STE valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.